[1]
|
ICH Harmonized Tripartite Guideline E14 (2005) E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf
|
[2]
|
Roden, D.M. (2004) Drug-Induced Prolongation of the QT Interval. The New England Journal of Medicine, 350, 1013-1022. http://dx.doi.org/10.1056/NEJMra032426
|
[3]
|
Brown, C.S., Farmer, R.G., Soberman, J.E. and Eichner, S.F. (2004) Pharmacokinetic Factors in the Adverse Cardiovascular Effects of Antipsychotic Drugs. Clinical Pharmacokinetics, 43, 33-56.
http://dx.doi.org/10.2165/00003088-200443010-00003
|
[4]
|
Glassman, A.H. and Bigger Jr., J.T., (2001) Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. American Journal of Psychiatry, 158, 1774-1782. http://dx.doi.org/10.1176/appi.ajp.158.11.1774
|
[5]
|
Mackin, P. and Young, A.H. (2005) QTc Interval Measurement and Metabolic Parameters in Psychiatric Patients Taking Typical or Atypical Antipsychotic Drugs: A Preliminary Study. Journal of Clinical Psychiatry, 66, 1386-1391.
http://dx.doi.org/10.4088/JCP.v66n1107
|
[6]
|
Montanez, A., Ruskin, J.N., Hebert, P.R., Lamas, G.A. and Hennekens, C.H. (2004) Prolonged QTc Interval and Risks of Total and Cardiovascular Mortality and Sudden Death in the General Population: A Review and Qualitative Overview of the Prospective Cohort Studies. Archives of Internal Medicine, 164, 943-948.
http://dx.doi.org/10.1001/archinte.164.9.943
|
[7]
|
Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J. and Thomas, S.H. (2000) QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients. Lancet, 355, 1048-1052. http://dx.doi.org/10.1016/S0140-6736(00)02035-3
|
[8]
|
Stollberger, C., Huber, J.O. and Finsterer, J. (2005) Antipsychotic Drugs and QT Prolongation. International Clinical Psychopharmacology, 20, 243-251. http://dx.doi.org/10.1097/01.yic.0000166405.49473.70
|
[9]
|
Taylor, D.M. (2003) Antipsychotics and QT Prolongation. Acta Psychiatrica Scandinavica, 107, 85-95.
http://dx.doi.org/10.1034/j.1600-0447.2003.02078.x
|
[10]
|
van Noord, C., Straus, S.M., Sturkenboom, M.C., Hofman, A., Aarnoudse, A.J., Bagnardi, V., et al. (2009) Psychotropic Drugs Associated with Corrected QT Interval Prolongation. Journal of Clinical Psychopharmacology, 29, 9-15.
http://dx.doi.org/10.1097/JCP.0b013e318191c6a8
|
[11]
|
Warner, J.P., Barnes, T.R. and Henry, J.A. (1996) Electrocardiographic Changes in Patients Receiving Neuroleptic Medication. Acta Psychiatrica Scandinavica, 93, 311-313. http://dx.doi.org/10.1111/j.1600-0447.1996.tb10653.x
|
[12]
|
Yang, F.D., Wang, X.Q., Liu, X.P., Zhao, K.X., Fu, W.H., Hao, X.R., et al. (2011) Sex Difference in QTc Prolongation in Chronic Institutionalized Patients with Schizophrenia on Long-Term Treatment with Typical and Atypical Antipsychotics. Psychopharmacology, 216, 9-16. http://dx.doi.org/10.1007/s00213-011-2188-5
|
[13]
|
Zemrak, W.R. and Kenna, G.A. (2008) Association of Antipsychotic and Antidepressant Drugs with Q-T Interval Prolongation. American Journal of Health-System Pharmacy, 65, 1029-1038. http://dx.doi.org/10.2146/ajhp070279
|
[14]
|
Haddad, P.M. and Anderson, I.M. (2002) Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs, 62, 1649-1671. http://dx.doi.org/10.2165/00003495-200262110-00006
|
[15]
|
Khan, M.M., Logan, K.R., McComb, J.M. and Adgey, A.A. (1981) Management of Recurrent Ventricular Tachyarrhythmias Associated with Q-T Prolongation. American Journal of Cardiology, 47, 1301-1308.
http://dx.doi.org/10.1016/0002-9149(81)90263-0
|
[16]
|
Leslie, D.L. and Rosenheck, R. (2012) Off-Label Use of Antipsychotic Medications in Medicaid. The American Journal of Managed Care, 18, e109-e117.
|
[17]
|
Wang, P.S., Schneeweiss, S., Avorn, J., Fischer, M.A., Mogun, H., Solomon, D.H., et al. (2005) Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications. The New England Journal of Medicine, 353, 2335-2341. http://dx.doi.org/10.1056/NEJMoa052827
|
[18]
|
Ito, H., Okumura, Y., Higuchi, T., Tan, C.H. and Shinfuku, N. (2012) International Variation in Antipsychotic Prescribing for Schizophrenia: Pooled Results from the Research on East Asia Psychotropic Prescription (Reap) Studies. Open Journal of Psychiatry, 2, 340-346. http://dx.doi.org/10.4236/ojpsych.2012.224048
|
[19]
|
Lelliott, P., Paton, C., Harrington, M., Konsolaki, M., Sensky, T. and Okocha, C. (2002) The Influence of Patient Variables on Polypharmacy and Combined High Dose of Antipsychotic Drugs Prescribed for In-Patients. Psychiatric Bulletin, 26, 411-414. http://dx.doi.org/10.1192/pb.26.11.411
|
[20]
|
Sim, K., Su, H.C., Fujii, S., Yang, S.Y., Chong, M.Y., Ungvari, G., et al. (2009) High-Dose Antipsychotic Use in Schizophrenia: A Comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) Studies. British Journal of Clinical Pharmacology, 67, 110-117. http://dx.doi.org/10.1111/j.1365-2125.2008.03304.x
|
[21]
|
Scott, R.P. (2010) Drug Interactions. NIH.
http://www.cc.nih.gov/training/training/principles/slides/DrugInteractions2010-2011_text.pdf
|
[22]
|
Rendic, S. (2002) Summary of Information on Human CYP Enzymes: Human P450 Metabolism Data. Drug Metabolism Reviews, 34, 83-448. http://dx.doi.org/10.1081/DMR-120001392
|
[23]
|
Ogu, C.C. and Maxa, J.L. (2000) Drug Interactions Due to Cytochrome P450. Baylor University Medical Center Proceedings, 13, 421-423.
|
[24]
|
Kobayashi, M., Ito, H., Okumura, Y., Mayahara, K., Matsumoto, Y. and Hirakawa, J. (2010) Hospital Readmission in First-Time Admitted Patients with Schizophrenia: Smoking Patients Had Higher Hospital Readmission Rate than Non-Smoking Patients. The International Journal of Psychiatry in Medicine, 40, 247-257.
http://dx.doi.org/10.2190/PM.40.3.b
|
[25]
|
Okumura, Y., Ito, H., Kobayashi, M., Mayahara, K., Matsumoto, Y. and Hirakawa, J. (2010) Prevalence of Diabetes and Antipsychotic Prescription Patterns in Patients with Schizophrenia: A Nationwide Retrospective Cohort Study. Schizophrenia Research, 119, 145-152. http://dx.doi.org/10.1016/j.schres.2010.02.1061
|
[26]
|
Christensen, P.K., Gall, M.A., Major-Pedersen, A., Sato, A., Rossing, P., Breum, L., et al. (2000) QTc Interval Length and QT Dispersion as Predictors of Mortality in Patients with Non-Insulin-Dependent Diabetes. Scandinavian Journal of Clinical & Laboratory Investigation, 60, 323-332. http://dx.doi.org/10.1080/003655100750046486
|
[27]
|
Saarnivaara, L., Klemola, U.M., Lindgren, L., Rautiainen, P. and Suvanto, A. (1990) QT Interval of the ECG, Heart Rate and Arterial Pressure Using Propofol, Methohexital or Midazolam for Induction of Anaesthesia. Acta Anaesthesiologica Scandinavica, 34, 276-281. http://dx.doi.org/10.1111/j.1399-6576.1990.tb03085.x
|
[28]
|
Inagaki, A. and Inada, T. (2006) Dose Equivalence of Psychotropic Drugs. Part 18: Dose Equivalence of Psychotropic Drugs: 2006-Version. Japanese Journal of Clinical Psychopharmacology, 9, 1443-1447. (in Japanese)
|
[29]
|
Bazett, H.C. (1920) The Time Relations of the Blood-Pressure Changes after Excision of the Adrenal Glands, with Some Observations on Blood Volume Changes. The Journal of Physiology, 53, 320-339.
|
[30]
|
Caccia, S. (2000) Biotransformation of Post-Clozapine Antipsychotics: Pharmacological Implications. Clinical Pharmacokinetics, 38, 393-414. http://dx.doi.org/10.2165/00003088-200038050-00002
|
[31]
|
Crouch, M.A., Limon, L. and Cassano, A.T. (2003) Clinical Relevance and Management of Drug-Related QT Interval Prolongation. Pharmacotherapy, 23, 881-908. http://dx.doi.org/10.1592/phco.23.7.881.32730
|
[32]
|
de Leon, J., Sandson, N.B. and Cozza, K.L. (2008) A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II. Psychosomatics, 49, 347-361.
http://dx.doi.org/10.1176/appi.psy.49.4.347
|
[33]
|
Desta, Z., Kerbusch, T., Soukhova, N., Richard, E., Ko, J.W. and Flockhart, D.A. (1998) Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide. Journal of Pharmacology and Experimental Therapeutics, 285, 428-437.
|
[34]
|
Fang, J., Baker, G.B., Silverstone, P.H. and Coutts, R.T. (1997) Involvement of CYP3A4 and CYP2D6 in the Metabolism of Haloperidol. Cellular and Molecular Neurobiology, 17, 227-233.
http://dx.doi.org/10.1023/A:1026317929335
|
[35]
|
Grimm, S.W., Richtand, N.M., Winter, H.R., Stams, K.R. and Reele, S.B. (2006) Effects of Cytochrome P450 3A Modulators Ketoconazole and Carbamazepine on Quetiapine Pharmacokinetics. British Journal of Clinical Pharmacology, 61, 58-69. http://dx.doi.org/10.1111/j.1365-2125.2005.02507.x
|
[36]
|
Lazarus, G.M. (2001) Gender-Specific Medicine in Pediatrics. The Journal of Gender-Specific Medicine, 4, 50-53.
|
[37]
|
Mizuno, Y., Tani, N., Komuro, S., Kanamaru, H. and Nakatsuka, I. (2003) In Vitro Metabolism of Perospirone in Rat, Monkey and Human Liver Microsomes. European Journal of Drug Metabolism and Pharmacokinetics, 28, 59-65.
http://dx.doi.org/10.1007/BF03190868
|
[38]
|
Muralidharan, G., Cooper, J.K., Hawes, E.M., Korchinski, E.D. and Midha, K.K. (1996) Quinidine Inhibits the 7-Hydroxylation of Chlorpromazine in Extensive Metabolisers of Debrisoquine. European Journal of Clinical Pharmacology, 50, 121-128. http://dx.doi.org/10.1007/s002280050079
|
[39]
|
Olesen, O.V. and Linnet, K. (2000) Identification of the Human Cytochrome P450 Isoforms Mediating in Vitro N-Dealkylation of Perphenazine. British Journal of Clinical Pharmacology, 50, 563-571.
http://dx.doi.org/10.1046/j.1365-2125.2000.00298.x
|
[40]
|
Perphenazine Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1172006F1030_1_07/
|
[41]
|
Pimozide Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179022C1034_1_07/
|
[42]
|
Quetiapine Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179042C1023_2_14/
|
[43]
|
Ray, W.A., Murray, K.T., Meredith, S., Narasimhulu, S.S., Hall, K. and Stein, C.M. (2004) Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. The New England Journal of Medicine, 351, 1089-1096.
http://dx.doi.org/10.1056/NEJMoa040582
|
[44]
|
Semla, T.P., Beizer, J.L. and Higbee, M.D. (2005) Geriatric Dosage Handbook. 10th Edition, Lexi Comp Inc, Hudson, 1286-1290.
|
[45]
|
Sharif, Z.A. (2003) Pharmacokinetics, Metabolism and Drug-Drug Interactions of Atypical Antipsychotics in Special Populations. Journal of Clinical Psychiatry, 5, 22-25.
|
[46]
|
Shiraga, T., Kaneko, H., Iwasaki, K., Tozuka, Z., Suzuki, A. and Hata, T. (1999) Identification of Cytochrome P450 Enzymes Involved in the Metabolism of Zotepine, an Antipsychotic Drug, in Human Liver Microsomes. Xenobiotica, 29, 217-229. http://dx.doi.org/10.1080/004982599238623
|
[47]
|
Tateishi, T., Watanabe, M., Kumai, T., Tanaka, M., Moriya, H., Yamaguchi, S., et al. (2000) CYP3A Is Responsible for N-Dealkylation of Haloperidol and Bromperidol and Oxidation of Their Reduced Forms by Human Liver Microsomes. Life Sciences, 67, 2913-2920. http://dx.doi.org/10.1016/S0024-3205(00)00874-2
|
[48]
|
Tyndale, R.F., Kalow, W. and Inaba, T. (1991) Oxidation of Reduced Haloperidol to Haloperidol: Involvement of Human P450IID6 (Sparteine/Debrisoquine Monooxygenase). British Journal of Clinical Pharmacology, 31, 655-660.
http://dx.doi.org/10.1111/j.1365-2125.1991.tb05588.x
|
[49]
|
Yukawa, E., Hokazono, T., Yukawa, M., Ichimaru, R., Maki, T., Matsunaga, K., et al. (2002) Population Pharmacokinetics of Haloperidol Using Routine Clinical Pharmacokinetic Data in Japanese Patients. Clinical Pharmacokinetics, 41, 153-159. http://dx.doi.org/10.2165/00003088-200241020-00006
|
[50]
|
Zhou, S.F. (2009) Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II. Clinical Pharmacokinetics, 48, 761-804. http://dx.doi.org/10.2165/11318070-000000000-00000
|
[51]
|
Bromperidol Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179028C1066_2_11/
|
[52]
|
Ozeki, Y., Fujii, K., Kurimoto, N., Yamada, N., Okawa, M., Aoki, T., et al. (2010) QTc Prolongation and Antipsychotic Medications in a Sample of 1017 Patients with Schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34, 401-405. http://dx.doi.org/10.1016/j.pnpbp.2010.01.008
|
[53]
|
Chong, S.A., Mythily, Lum, A., Goh, H.Y. and Chan, Y.H. (2003) Prolonged QTc Intervals in Medicated Patients with Schizophrenia. Human Psychopharmacology, 18, 647-649. http://dx.doi.org/10.1002/hup.540
|
[54]
|
Fluphenazine Decanoate Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1172405A1031_2_07/
|
[55]
|
Beach, S.R., Celano, C.M., Noseworthy, P.A., Januzzi, J.L. and Huffman, J.C. (2013) QTc Prolongation, Torsades de Pointes and Psychotropic Medications. Psychosomatics, 54, 1-13. http://dx.doi.org/10.1016/j.psym.2012.11.001
|
[56]
|
Haloperidol Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179020C1191_1_11/
|
[57]
|
Haloperidol Decanoate Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179406A1037_2_09/
|
[58]
|
Levomepromazine Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1172014B2056_1_13/
|
[59]
|
Nemonapride Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179036F1024_1_01/
|
[60]
|
Harrigan, E.P., Miceli, J.J., Anziano, R., Watsky, E., Reeves, K.R., Cutler, N.R., et al. (2004) A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, in the Absence and Presence of Metabolic Inhibition. Journal of Clinical Psychopharmacology, 24, 62-69. http://dx.doi.org/10.1097/01.jcp.0000104913.75206.62
|
[61]
|
Olanzapine Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179044F4028_1_18/
|
[62]
|
Desta, Z., Kerbusch, T. and Flockhart, D.A. (1999) Effect of Clarithromycin on the Pharmacokinetics and Pharmacodynamics of Pimozide in Healthy Poor and Extensive Metabolizers of Cytochrome P450 2D6 (CYP2D6). Clinical Pharmacology & Therapeutics, 65, 10-20. http://dx.doi.org/10.1016/S0009-9236(99)70117-7
|
[63]
|
Risperidone Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1179038C1027_1_27/
|
[64]
|
Trifluoperazine Package Insert (2013) http://www.info.pmda.go.jp/go/pack/1172008F1021_2_07/
|
[65]
|
Bai, C.X., Kurokawa, J., Tamagawa, M., Nakaya, H. and Furukawa, T. (2005) Nontranscriptional Regulation of Cardiac Repolarization Currents by Testosterone. Circulation, 112, 1701-1710.
http://dx.doi.org/10.1161/CIRCULATIONAHA.104.523217
|
[66]
|
Shuba, Y.M., Degtiar, V.E., Osipenko, V.N., Naidenov, V.G. and Woosley, R.L. (2001) Testosterone-Mediated Modulation of HERG Blockade by Proarrhythmic Agents. Biochemical Pharmacology, 62, 41-49.
http://dx.doi.org/10.1016/S0006-2952(01)00611-6
|
[67]
|
Ramirez, A.H., Schildcrout, J.S., Blakemore, D.L., Masys, D.R., Pulley, J.M., Basford, M.A., et al. (2011) Modulators of Normal Electrocardiographic Intervals Identified in a Large Electronic Medical Record. Heart Rhythm, 8, 271-277.
http://dx.doi.org/10.1016/j.hrthm.2010.10.034
|